Every year, millions of couples turn to in vitro fertilization (IVF) as their path to parenthood. But a surprising discovery is challenging how fertility clinics have screened eggs for the past four decades: **more than half of IVF patients may be losing viable, healthy eggs without even knowing it**. A new automated technology called FIND-Chip is revealing that manual egg screening, the standard practice since the early days of IVF, is missing eggs that could successfully develop into embryos and lead to pregnancy. Infertility affects 8 to 12 percent of reproductive-aged couples worldwide, making IVF one of the most important fertility treatments available. Yet despite decades of innovation in how eggs are fertilized, cultured, and preserved, the actual process of finding eggs in the fluid collected during egg retrieval has remained largely unchanged. Embryologists manually scan under a microscope through complex fluid containing blood cells, tissue fragments, and other debris to locate eggs embedded in cumulus tissue. It is painstaking work that depends entirely on human skill and attention. What Is Follicular Fluid and Why Does It Matter? When a woman undergoes ovarian stimulation for IVF, doctors retrieve fluid from the ovarian follicles where eggs develop. This fluid, called follicular fluid, contains the eggs along with many other cells and tissue fragments. The challenge is that follicular fluid varies dramatically from patient to patient and clinic to clinic, depending on stimulation protocols, retrieval techniques, and individual physiology. Some samples are thick with blood cells; others contain varying amounts of tissue debris. For four decades, trained embryologists have been the only reliable way to sort through this complexity and find the eggs. The limitations of manual screening became starkly apparent in a clinical study involving 582 patients across four IVF centers. Researchers used FIND-Chip to process follicular fluid samples that had already been screened and discarded by embryologists using standard practice. The results were striking: the device recovered 583 eggs from those pre-screened, discarded samples. In other words, in more than 50 percent of cases, viable eggs were being inadvertently thrown away. How Does the New Technology Work? FIND-Chip is a microfluidic device, meaning it uses tiny channels and precise fluid control to manipulate and sort cells. The device automates four critical tasks in sequence. First, it filters the complex, tissue-dense follicular fluid sample. Second, it removes the cumulus cells surrounding each egg through a process called denudation, using controlled fluid oscillation cycles. Third, it concentrates the egg suspension by approximately 100 times, making the eggs easier to work with. Finally, it captures the eggs in a specific location on the chip, ready for fertilization or freezing. The entire process is controlled by an automated instrument that regulates fluid flow, ensuring that eggs from different patients experience the same mechanical treatment and fluidic forces. This standardization is crucial because it removes the variability that comes with manual screening. The device processes tens of milliliters of follicular fluid and produces a small droplet containing 100 to 500 microliters of denuded eggs ready for the next steps in IVF treatment. Steps to Understand How FIND-Chip Improves IVF Outcomes - Automated Screening: The device replaces manual microscope screening with microfluidic automation, reducing human error and ensuring consistent processing across all patient samples regardless of follicular fluid composition. - Recovery of Missed Eggs: By processing pre-screened and discarded fluid, FIND-Chip identified eggs that embryologists had overlooked, recovering 583 eggs from 582 patients in the clinical study. - Maintained Egg Quality: The automated process preserves egg viability and development potential, with recovered eggs successfully developing into high-quality blastocysts suitable for embryo transfer or freezing. - Standardized Processing: Automation ensures that all patient samples are processed with identical fluidic protocols, eliminating variability caused by differences in embryologist technique or attention. What Do the Clinical Results Show? The real-world impact of FIND-Chip extends beyond the numbers. In a pilot trial with 19 patients, two gained additional blastocysts for their treatment using eggs recovered from pre-screened follicular fluid. One of those patients achieved a live birth from an egg that would have otherwise been discarded. For that patient, FIND-Chip made the difference between going home empty-handed and becoming a parent. This outcome is particularly significant for patients with low ovarian reserve, meaning they produce fewer eggs during stimulation. For these patients, losing even one viable egg can mean the difference between a successful cycle and a failed one. The emotional and financial toll of repeated IVF cycles is substantial, making the recovery of every possible egg critically important. The eggs recovered by FIND-Chip were not inferior or questionable. They successfully developed into high-quality blastocysts, the stage at which embryos are typically transferred into the uterus or frozen for future use. This demonstrates that the eggs being missed by manual screening are genuinely viable and capable of supporting pregnancy. Why Has Manual Screening Remained Unchanged for 40 Years? Despite transformational advances in IVF over the past four decades, from improved hormone stimulation protocols to intracytoplasmic sperm injection (ICSI), a procedure where a single sperm is injected directly into an egg, and egg freezing technology, the initial step of finding eggs in follicular fluid has remained stubbornly manual. This is partly because follicular fluid presents unique challenges that have been difficult to solve with traditional microfluidic approaches. The fluid contains large volumes, complex tissue composition, and highly variable characteristics from sample to sample. IVF clinics have relied on highly skilled embryologists and strict quality control measures to minimize variability in outcomes. However, this approach has inherent limitations. Even the most experienced embryologist can miss eggs, especially when processing dozens of samples in a single day. The manual process is also labor-intensive, which increases costs and limits access to IVF treatment for patients who need it most. What Does This Mean for the Future of IVF? As demand for IVF continues to grow worldwide, clinics face mounting pressure to improve efficiency, reduce costs, and expand access to treatment. Automation of the egg screening process addresses all three challenges. By removing the manual bottleneck and standardizing a critical step in the IVF laboratory workflow, FIND-Chip and similar technologies could help clinics serve more patients while improving success rates. The broader implication is that IVF success rates, currently at best 50 percent for patients with good prognosis, may be artificially limited by the loss of viable eggs during screening. If clinics can recover the eggs currently being discarded, the embryo pool available for each patient expands, increasing the chances of a successful pregnancy. For patients who have struggled with infertility, this represents a meaningful opportunity to improve their odds without requiring additional hormone stimulation or additional egg retrieval procedures. The development of FIND-Chip also signals a broader shift in reproductive medicine toward automation and standardization. As microfluidic technologies continue to advance, other labor-intensive steps in the IVF laboratory, from sperm selection to embryo culture to egg freezing, may also benefit from automated solutions. The goal is to make IVF more efficient, more accessible, and ultimately more successful for the millions of couples worldwide who depend on it to build their families.
